Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7387-7396
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7387
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7387
Relapse (n = 47) | Remission (n = 102) | P | |
Age (in yr, mean ± SD, range) | 43.9 ± 17.5 (17-76) | 38.1 ± 14.6 (17-76) | NS |
Male | 28 (59.6%) | 49 (48.0%) | 0.078 |
Disease duration (in mo, mean ± SD, range) | 95.1 ± 118.7 (1-560) | 95.3 ± 162.0 (1-1415) | NS |
Diagnosis | |||
Crohn’s disease | 38 (80.9%) | 75 (73.5%) | NS |
Ulcerative Colitis | 9 (19.1%) | 27 (26.5%) | NS |
Disease location | NS | ||
Ileal (L1) | 16 | 22 | |
Colonic (L2) | 4 | 14 | |
Ileocolonic (L3) | 28 | 29 | |
Perianal disease (p) | 7 | 11 | |
Proctitis | 1 | 7 | |
Left sided | 3 | 8 | |
Extensive | 5 | 12 | |
Extraintestinal manifestations | 18 | 35 | NS |
Fecal calprotectin (in μg/g, median, IQR) | 481 (286-600) | 89 (36-180.8) | < 0.001 |
CRP (in yr, mean ± SD, range) | 11.3 ± 10.1 (3.0-41.0) | 5.1 ± 5.5 (3.1-42.0) | 0.002 |
WBC (in thousands, mean ± SD, range) | 8.9 ± 3.3 (3.4-18.2) | 7.5 ± 2.4 (3.8-18.4) | 0.022 |
Hgb (in g/dL, mean ± SD, range) | 13.2 ± 1.9 (9.7-16.5) | 13.6 ± 1.5 (10.0-16.4) | NS |
PLT (in thousands, mean ± SD, range) | 277.5 ± 99.5 (117-511) | 256.0 ± 61.4 (103-450) | NS |
Disease flare | ||||
Univariate | Multivariate | |||
HR (95%CI) | P | HR (95%CI) | P | |
FC (HR per 100 μg/g) | 1.212 (1.147-1.280) | < 0.001 | 1.745 (1.275-2.388) | 0.001 |
Age (in yr) | 1.018 (0.998-1.037) | 0.055 | 0.973 (0.937-1.011) | NS |
Gender (male vs female) | 0.577 (0.322-1.033) | 0.064 | 0.643 (0.151-2.749) | NS |
Disease duration (in mo) | 1.000 (0.998-1.002) | > 0.2 | ||
Disease (UC vs CD) | 1.373(0.664-2.838) | > 0.2 | ||
Extraintestinal manifestations (none vs present) | 1.085 (0.856-1.375) | > 0.2 | ||
Treatment at baseline | 0.915 (0.650-1.287) | > 0.2 | ||
5-ASA | 0.408 (0.125-1.331) | 0.137 | 8.805 (0.753-102.913) | NS |
Immunomodulators (AZA, 6-MP) | 1.193 (0.575-2.474) | > 0.2 | ||
Anti-TNF | 0.754 (0.391-1.455) | > 0.2 | ||
Previous Surgery for disease | 1.494 (0.591-3.776) | > 0.2 | ||
CRP (HR per 1mg/dL) | 1.062 (1.034-1.091) | < 0.001 | 1.010 (0.935-1.093) | NS |
WBC (HR per 1000) | 1.144 (1.028-1.273) | 0.014 | 1.197 (1.001-1.432) | 0.049 |
Hgb (HR per 1 g/dL) | 0.887 (0.702-1.121) | > 0.2 | ||
PLT (HR per 1000) | 1.003 (0.998-1.008) | > 0.2 |
- Citation: Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396
- URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7387.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7387